Tumor suppressors with extracellular function are likely to have advantages as targets for cancer therapy, but few are known. Here, we focused on angiopoietin-like 4 (ANGPTL4), which is a secreted glycoprotein involved in lipoprotein metabolism and angiogenesis, is methylation-silenced in human cancers, but has unclear roles in cancer development and progression. We found a deletion mutation in its coiled-coil domain at its N-terminal in human gastric cancers, in addition to hypermethylation of the ANGPTL4 promoter CpG islands. Forced expression of wild-type ANGPTL4, but not ANGPTL4 with the deletion, at physiological levels markedly suppressed in vivo tumorigenicity and tumor angiogenesis, indicating that the latter caused the former. Tumor-derived ANGPTL4 suppressed in vitro vascular tube formation and proliferation of human umbilical vascular endothelial cells, partly due to suppression of ERK signaling. These showed that ANGPTL4 is a genetically and epigenetically inactivated secreted tumor suppressor that inhibits tumor angiogenesis.
INTRODUCTION
Tumor-suppressor genes (TSGs) are somatically inactivated by genetic and/or epigenetic mechanisms. 1, 2 Targeting TSGs for molecular target therapy has been attempted mainly for p53. 3, 4 However, the attempts have not been easy, partly due to the fact that the p53 gene product is neither a cell surface protein nor a typical enzyme. 5 Considering efficient delivery to targets, TSGs whose products function extracellularly as secreted proteins are likely to have advantages. So far, secreted frizzled-related proteins are known as secreted tumor suppressors, 6 ,7 but few others are known. As a candidate, we previously identified that angiopoietin-like 4 (ANGPTL4), a member of the angiopoietin-like family, was silenced by aberrant DNA methylation of promoter CpG islands (CGIs) (methylation-silenced) in human cancers. 8, 9 ANGPTL4 is a secreted glycoprotein, and is involved in lipoprotein metabolism through inhibition of lipoprotein lipase. 10 In contrast, the role of ANGPTL4 in angiogenesis remains controversial. [11] [12] [13] [14] [15] Likewise, its role in tumor formation also remains controversial-some reports suggesting its tumor-suppressive function 12, 16, 17 and others its oncogenic function. [18] [19] [20] Here, we aimed to clarify the role of ANGPTL4 in cancer development and progression and also in tumor angiogenesis.
RESULTS AND DISCUSSION
Inactivation of ANGPTL4 by epigenetic and genetic mechanisms in human gastric cancers ANGPTL4 methylation was detected in 10 of 91 human gastric cancers (11%) by quantitative real-time methylation-specific PCR (Figure 1a) . The mRNA and protein expression levels of ANGPTL4 in cancers with ANGPTL4 methylation were significantly lower than those in cancers without methylation (Supplementary Figure S2) . Methylation status did not have any association with clinicopathological features, but had a significant association with Epstein-Barr virus infection status and the presence of the CGI methylator phenotype 21 (Supplementary Figure S1 and  Supplementary Table S1 ). In non-cancerous gastric mucosae of 71 gastric cancer patients and gastric mucosae of 58 healthy volunteers, the methylation level was also quantified. It was significantly higher in cancer patients than in healthy volunteers and in individuals with H. pylori infection than in those without (Figure 1b) . This suggested the potential involvement of ANGPTL4 methylation in the formation of an epigenetic field for cancerization, a predisposed normal-appearing tissue.
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ANGPTL4 mutation was then analyzed in 89 of the 91 gastric cancers (due to sample availability), and a somatic 21-bp deletion in exon 1 was identified in one specimen (cancer #217T) without ANGPTL4 methylation (Figures 1c and d) . ANGPLT4 consists of an N-terminal coiled-coil domain (CCD) and a C-terminal fibrinogenlike domain, 23, 24 and the 21-bp deletion was located in the CCD (Supplementary Figure S3) . The CCD is reported to be critical for regulation of the anti-angiogenic activity of ANGPTL4, 13 and the deletion here involved one of the two cysteine residues (Cys76 and Cys80) essential for the activity regulation by oligomerization. 25, 26 Loss of heterozygosity (LOH), which suggests the presence of a TSG, 27 was detected in 4 of 16 samples (25%) informative for a C/T polymorphism at the second position of codon 266. The locus of 1 Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan; ANGPTL4, 19p13.3, has been suggested to contain TSGs, due to frequent LOH of the region in several types of cancers, such as pancreatic and colon cancers. [28] [29] [30] In addition, two human gastric cancer cell lines (MKN28 and AGS) without ANGPTL4 expression had methylation of its promoter, and their treatment with 5-aza-2 0 -deoxycytidine (5-aza-dC), a DNA methylation inhibitor, Figure 1 . Aberrant methylation and a mutation of ANGPTL4 in human gastric cancers, and methylation in non-cancerous gastric mucosae. (a) ANGPTL4 methylation levels in gastric cancer specimens. Cancer samples were obtained from 91 gastric cancer patients undergoing gastrectomy with informed consents and approval by the institutional review boards. Some of the samples and methylation data were obtained from our previous study. 33 Quantitative real-time methylation-specific PCR was conducted with sodium bisulfite-treated DNA and primer sets specific to methylated and unmethylated sequences (Supplementary Table S2 ). Using a cutoff value of 6% (broken line), as in previous studies, [34] [35] [36] 10 cancer specimens were considered to have aberrant methylation. (b) ANGPTL4 methylation levels in gastric mucosae of 58 healthy volunteers (30 male and 28 female; average age ¼ 55 years) and 71 non-cancerous gastric mucosae of gastric cancer patients (50 male and 21 female; average age ¼ 67 years) obtained by endoscopic biopsy of the antral region. H. pylori infection status was analyzed by a serum anti-H. pylori IgG antibody test (SRL, Tokyo, Japan), rapid urease test (Otsuka, Tokushima, Japan) or culture test (Eiken, Tokyo, Japan). The methylation level in gastric mucosae was significantly higher in gastric cancer patients than in healthy volunteers. The mean methylation level is shown by a horizontal line. *Po0.05, **Po0.01 (the unpaired Welch's t-test, two-sided). (c) A deletion mutation in a human gastric cancer specimen. All the seven exons and splice donor/acceptor sites of ANGPTL4 were amplified by PCR (Supplementary Table S2) , and the PCR products were directly cycle sequenced. The sequences of a gastric cancer specimen (217T) and its corresponding non-cancerous tissue (217N) between nucleotides 385 and 423 are shown. A 21-bp deletion in exon 1 was detected (shown in the gray background). (d) Confirmation of the deletion mutation using DNA samples obtained from a single tissue section. A 117-bp region encompassing the deletion was amplified by PCR, and the deletion was detected as a PCR product with a shorter size (96 bp). DNA from the cancer (T1), but not that from non-cancerous areas (N1 and N2), yielded the shorter product (shown by arrows). T*, genomic DNA extracted from frozen tumor tissues. If LOH was present in T1, the band intensity ratio was expected to be 1:1 (wild type:deletion mutant) (fraction of cancer cells was pathologically assessed to be 61-67%). If LOH was not present, it was expected to be 2:1. The ratio observed was B1:2, and LOH was considered to be present in T1. Figure S4) . This showed methylation silencing of ANGPTL4 in these cell lines.
Marked suppression of in vivo tumor growth by ANGPTL4, but not by a mutant with the deletion The function of ANGPTL4, along with its mutant with the deletion, was examined by stably introducing wild-type or mutant ANGPTL4 complementary DNA into MKN28 and AGS. The expression levels of the exogenous wild-type ANGPTL4 and its mutant were kept in the range comparable to its physiological expression in gastric mucosae (Supplementary Figure S5a) , and expression of ANGPTL4 with the deletion mutation was confirmed by the amplification of a shorter size fragment (Supplementary Figure S5b) . Regarding in vitro effects, the ANGPTL4 expression did not affect cell morphology, motility or cell growth (Supplementary Figures  S6-S8) . However, in vivo, sizes of engrafted tumors were strikingly suppressed by the wild-type ANGPTL4, markedly in AGS and almost completely in MKN28 (Figure 2) . In contrast, when the mutant ANGPTL4 was expressed in MKN28, it did not show any anti-tumorigenic effect. The presence of ANGPTL4 mRNA and protein expression in the transplanted tumors was confirmed ( Supplementary Figures S9 and S10 ). The role of ANGPTL4 in tumor development and progression has been highly controversial, but our data clearly showed that ANGPTL4 suppresses tumor formation, at least in gastric cancers.
Inhibition of tumor angiogenesis as a mechanism for tumor suppression As a mechanism for tumor suppression by ANGPTL4, antiangiogenic activity of tumor-derived ANGPTL4 was examined. We performed an in vivo Matrigel plug angiogenesis assay to observe the vascularization that invades into a Matrigel 31 using MKN28 cells with control (EGFP), ANGPTL4, and its mutant with the deletion. Ten days after subcutaneous transplantation, the Matrigel plugs containing the control cells showed a high degree of blood vessel recruitment, as visualized by the high content of hemoglobin ( Figure 3 ) and by the staining of CD31-positive vascular endothelial cells (Supplementary Figure S11) . In contrast, the Matrigel plugs containing the ANGPTL4-expressing cells showed a marked suppression of the blood vessel recruitment. However, ANGPTL4 with the deletion mutation did not have such activity. The lack of the suppressive effect was in accordance with a report that the CCD was essential for the interaction with the extracellular matrix and for its in vivo suppressive activity. 13 These results strongly indicated that the marked anti-angiogenic activity of tumor-derived ANGPTL4 was the cause of the marked suppression of tumor growth by ANGPTL4.
Mechanisms for the anti-angiogenic activity of the tumor-derived ANGPTL4 The mechanisms of how tumor-derived, secreted ANGPTL4 exerts its anti-angiogenic effect were analyzed. First, we conducted a vascular tube formation assay using human umbilical vein endothelial cells (HUVECs). A conditioned medium from ANGPTL4-expressing cells suppressed vascular tube formation of HUVECs, as visualized by staining with anti-CD31antibody (Figure 4a) , and all the parameters to assess vascular formation were markedly suppressed (Figure 4b ). This result showed that a large part of the anti-angiogenic activity of tumor-derived ANGPTL4 was mediated by the suppression of vascular tube formation in the tumor microenvironment.
The effect of the conditioned medium on the growth of HUVECs was then analyzed. The conditioned medium from cells expressing ANGPTL4, but not that from cells expressing its mutant with the deletion, suppressed the growth (Figure 4c ). Cell cycle analysis showed that the conditioned medium from ANGPTL4-expressing cells significantly increased the number of cells in the S phase, suggesting that it induced an S-phase arrest (Figure 4d) . However, the amount of p21, a potential inducer of the S-phase arrest, 32 was not increased (Figure 4e ). No induction of apoptosis was observed by western blot analysis of apoptosis-related proteins, cleaved Caspase-3 and cleaved PARP (Figure 4e ), or by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Supplementary Figure S8) .
Finally, the effect of tumor-derived ANGPTL4 on the MAPK signaling was analyzed. The conditioned medium from the ANGPTL4-expressing cells clearly inhibited the phosphorylation of ERK1/2 (pERK1/2) (Figure 4e) , and the phosphorylation of its immediate upstream mediator, pMEK, was in contrast increased. The conditioned medium from the cells expressing the mutant with the deletion showed a similar activity to that of the ANGPTL4-expressing cells. As CCD is not important for the delivery to target cells in vitro and the fibrinogen-like domain is important for inhibition of the Raf/MEK/ERK signaling, 11 it was considered that the deletion mutation did not affect the inhibition activity.
This study demonstrated that ANGPTL4 is a mutated and methylation-silenced tumor suppressor whose product is secreted and inhibits angiogenesis. ANGPTL4 mutation (loss-of-function) was identified for the first time in any type of cancers, and the anti-angiogenic activity of tumor-derived ANGPTL4 was shown here also for the first time. These data warrant further research into utilizing ANGPTL4 as a target of anti-angiogenesis cancer therapy.
